Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05387031

Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

View on ClinicalTrials.gov

Summary

This study intends to select patients with confirmed moderate-to-severe Crohn's disease (CD) and obstructive symptoms of intestinal stenosis, who have clear evidence of lumen stenosis caused by the disease itself through radiography or endoscopy. After the informed consent of the patients, comprehensive drug therapy with ustekinumab as the mainstay was performed. The basic information and medical history of the patients were collected, and the treatment process of the patients was followed up and recorded, and the drug regimen was adjusted according to the physician's experience and judgment. At different follow-up time points, blood, feces, tissue and other specimens of patients were collected according to the situation, and gastrointestinal endoscopy, imaging examination, laboratory index examination, self-assessment of subjects' symptoms, and nutritional risk screening were performed on the patients. This study evaluated the CD disease activity, obstructive symptoms, and radiographic or endoscopic remission in patients at different follow-up time points, and comprehensively evaluated the efficacy of ustekinumab in relieving stenotic CD and its related factors.

Official title: Efficacy of Ustekinumab-based Integrated Medicine Therapy in Patients With Symptomatic Stricturing Crohn's Disease: a Multicenter, Prospective, Observational Cohort Study

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

OBSERVATIONAL

Enrollment

239

Start Date

2024-08-01

Completion Date

2028-08-01

Last Updated

2026-02-27

Healthy Volunteers

No

Interventions

DRUG

Ustekinumab

The initial intravenous (IV) infusion with ustekinumab at baseline was weight-adjusted (260 mg ≤55 kg, 390 mg between 55 and 85 kg, 520 mg ≥85 kg). According to the label, the first subcutaneous (SC) 90 mg induction dose was administered at week 8 followed by a maintenance dose of 90 mg SC every 8 or 12 weeks, at the discretion of the physician. This study evaluated the CD disease activity, obstructive symptoms, and radiographic or endoscopic remission in patients at different follow-up time points, and comprehensively evaluated the efficacy of ustekinumab in relieving stenotic CD and its related factors.

Locations (8)

Department of Gastroenterology, Seventh Medical Center of PLA Army General Hospital

Beijing, Beijing Municipality, China

Department of Gastroenterology, Chongqing Renji Hospital, University of Chinese Academy of Sciences

Chongqing, Chongqing Municipality, China

Department of Gastroenterology, Sixth Affiliated Hospital, Sun Yat-Sen University

Guangzhou, Guangdong, China

Department of Gastroenterology, Huai'an First People's Hospital

Huai'an, Jiangsu, China

Department of Gastroenterology, Second Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China

Department of Gastroenterology, Affiliated Hospital of Yangzhou University

Yangzhou, Jiangsu, China

Center of Inflammatory Bowel Disease, Department of Gastroenterology, the Second Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

Department of Gastroenterology, The First Affiliated Hospital of Zhejiang Chinese Medical University

Hangzhou, Zhejiang, China